Michael Andriole

Chief Executive Officer bei CHIMERIX, INC.

Vermögen: 398 296 $ am 30.04.2024

51 Jahre

Health Technology

Consumer Services

Aktive Positionen von Michael Andriole

Unternehmen	Position	Beginn	Ende
CHIMERIX, INC.	Director/Board Member	01.08.2023	-
	Chief Executive Officer	01.08.2023	-
	President	01.08.2023	-
	Director of Finance/CFO	31.05.2019	01.08.2023
	Corporate Officer/Principal	08.04.2019	31.05.2019

Unternehmen	Position	Beginn	Ende
ENDOCYTE, INC.	Director of Finance/CFO	21.02.2017	01.12.2018
ELI LILLY AND COMPANY	Corporate Officer/Principal	01.08.2006	01.02.2017

Kelley School of Business	Masters Business Admin
Williams College of Business	Undergraduate Degree

International

Vereinigte Staaten

Operativ

Director of Finance/CFO	2
Corporate Officer/Principal	2
Undergraduate Degree	1

Sektoral

Health Technology	4
Consumer Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	2
ELI LILLY AND COMPANY	Health Technology
CHIMERIX, INC.	Health Technology

Private Unternehmen	1
Endocyte, Inc. Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.	Health Technology

Private Unternehmen

Health Technology